Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

St. Jude Medical Announces CE Mark Approval Of Ellipse ICD - Quick Facts

RELATED NEWS
Trade STJ now with 

St. Jude Medical, Inc. (STJ: Quote) announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator, or ICD. ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms that often lead to sudden cardiac death.

According to the company, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.

Dr. L.R.C. Dekker, cardiologist from the Cardiac Center of the Catharina Hospital in Eindhoven, The Netherlands, who implanted the first Ellipse ICD in Europe, said, "Its thinness, longevity and new discrimination algorithms constitute the answers to the three main concerns of patients and their doctors: decreasing the volume of the can, reducing the risk for infection during ICD replacement and minimizing inappropriate shock."

Click here to receive FREE breaking news email alerts for St. Jude Medical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that it swung to a second quarter loss, hurt by higher costs and expenses even as revenue surged 47%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.